All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View multiple myeloma content recommended for you
The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Nikhil Munshi, Dana-Farber Cancer Institute, Boston, US, answers the question: How has our understanding of the initiation of multiple myeloma changed over recent years?
Professor (Prof.) Munshi provides an overview of the advances made in the field of genomics in myeloma, such as in our knowledge of the chronological order of these changes. For example, it has been established that copy number changes are early events which are present in MGUS, smoldering multiple myeloma (MM) and MM. These are predominantly trisomies and translocations.
Additionally, Prof. Munshi discusses some of the abstracts presented during the ASH meeting, such as one using whole genome sequencing, and one on the concept of link RNA. Prof. Munshi concludes that our increased understanding of how myeloma develops may lead us to new therapeutic targets.
How has our understanding of the initiation of MM changed over recent years?
Your opinion matters
Which of the following factors is most important to you when selecting a treatment for patients with multiple myeloma?